BIOSEEKER GROUP AB - PRWeb Press Release Account Feed http://www.rsspad.com/rss2a/45006.xml BIOSEEKER GROUP AB - Press Releases en xml@emediawire.com xml@emediawire.com 30 New Intelligence Products for the Analysis of Prostate Cancer Therapeutics http://www.prweb.com/releases/2004/10/prweb165771.htm BioSeeker Intelligence and Research Units have collaborated to jointly develop several products that enable our customers to analyze business development opportunities and R& status in the field of prostate cancer therapeutics. BioSeeker Group has identified more than 300 companies and at least 50 different candidate drugs or combinations that have reached Phase III. Hundreds of investigational drugs are in different development stages today. Our Prostate Cancer Database includes more than 3500 records from a multitude of information sources. (PRWeb Oct 11, 2004)

Read the full story at http://www.prweb.com/releases/2004/10/prweb165771.htm

]]> http://www.prweb.com/releases/2004/10/prweb165771.htm Analytical Tool: Avastin & The Competitive Landscape http://www.prweb.com/releases/2004/10/prweb165767.htm Bioseeker's Intelligence Unit releases the ultimate tool to analyze the future competitive situation for Avastin. Reasons to own this Analytical Tool. This is the only product that provides you with a complete structure of the areas involved in analyzing Avastin. It covers areas such as: colorectal, breast and lung cancer, monoclonal antibodies, antiangiogenesis, protein kinase inhibitors, and VEGF/VEGFr inhibition. You will be able to study areas in conjunction to Avastin, structured by cancer type, drug effect and drug mechanisms/targets. To track cutting edge competitive companies, therapies and technologies in the future market. You will save time by rapid identification and analysis of competitors. Evaluate progress in both standard cytotoxic as well as novel treatments competing with Avastin. (PRWeb Oct 11, 2004)

Read the full story at http://www.prweb.com/releases/2004/10/prweb165767.htm

]]> http://www.prweb.com/releases/2004/10/prweb165767.htm Competitive Outlook on HCV: What to Know and Expect in R& and Business Development http://www.prweb.com/releases/2004/09/prweb161209.htm BioSeeker announces the release of a new report entitled "Competitive Outlook on HCV: What to Know and Expect in R& and Business Development". BioSeeker has in this report taken a fresh look on both the current world status of R& and business development in HCV. Our research and analysis is built on more than 150 companies from over 18 different countries and include more than 160 pipline drugs in development for HCV. (PRWeb Sep 28, 2004)

Read the full story at http://www.prweb.com/releases/2004/09/prweb161209.htm

]]> http://www.prweb.com/releases/2004/09/prweb161209.htm Guide to Venture Capital in European Biopharma http://www.prweb.com/releases/2004/09/prweb161208.htm BioSeeker announces the release of a new report entitled "Guide to Venture Capital in European Biopharma". Acting as a tool for planning and preparing your fund raising campaign, this report contains information that will help you understand the current investment climate, face the most critical issues for obtaining financing and help you understand how to localise and approach suitable investors. BioSeeker has localised and listed 111 active venture capital investors in European biopharma. Further, we have mapped down the biopharma deals of these investors throughout 2002 until the end of August 2004. Using this unique and near-to-complete investment data, BioSeeker has conducted several trend analyses of investments in the European Biopharma Industry. (PRWeb Sep 27, 2004)

Read the full story at http://www.prweb.com/releases/2004/09/prweb161208.htm

]]> http://www.prweb.com/releases/2004/09/prweb161208.htm Will Angiotensin II receptor blockers (ARBs) be the future in hypertensive treatment? http://www.prweb.com/releases/2004/09/prweb161215.htm This press release highlight future changes in the treatment of hypertension. You will be updated on new anti-hypertensive drug combinations and learn more about the future market development. (PRWeb Sep 25, 2004)

Read the full story at http://www.prweb.com/releases/2004/09/prweb161215.htm

]]> http://www.prweb.com/releases/2004/09/prweb161215.htm BioSeeker Group Valuates the Cancer Prevention Market http://www.prweb.com/releases/2004/06/prweb133845.htm The quest for primary and secondary cancer prevention has been ongoing for some years. Drug developers in the oncology arena have much to learn from their cardiovascular counterparts. (PRWeb Jun 16, 2004)

Read the full story at http://www.prweb.com/releases/2004/06/prweb133845.htm

]]> http://www.prweb.com/releases/2004/06/prweb133845.htm BioSeeker Group Continues Study on Late Stage Protein Kinase Inhibitors http://www.prweb.com/releases/2004/06/prweb130529.htm BioSeeker Group has studied the progress of late developmental stage protein kinase inhibitor projects. (PRWeb Jun 3, 2004)

Read the full story at http://www.prweb.com/releases/2004/06/prweb130529.htm

]]> http://www.prweb.com/releases/2004/06/prweb130529.htm Study on The Impact of New Drugs For The Treatment of Lung Cancer http://www.prweb.com/releases/2004/05/prweb125592.htm A new study guide you through the latest events of importance for understanding the progress in NSCLC cancer therapeutics. (PRWeb May 14, 2004)

Read the full story at http://www.prweb.com/releases/2004/05/prweb125592.htm

]]> http://www.prweb.com/releases/2004/05/prweb125592.htm Rapid Progression in Ion Channel Drug Discovery are Expected http://www.prweb.com/releases/2004/05/prweb125330.htm BioSeeker Group has studied new progress in ion channel drug discovery. Several factors point towards a fast development in this field. Increased knowledge of novel targets in combination with a strong progress in drug discovery technologies has strongly contributed to this fast development. Resulting in a variety of commercial opportunities. (PRWeb May 13, 2004)

Read the full story at http://www.prweb.com/releases/2004/05/prweb125330.htm

]]> http://www.prweb.com/releases/2004/05/prweb125330.htm BioSeeker Group Study Progress in Cancer Vaccine Strategies http://www.prweb.com/releases/2004/04/prweb118496.htm Progress in cancer vaccine strategies is continuing. Due to a harsh economical climate many companies have focused internally and on late stage candidates. This has lead to a somewhat lower activity in almost all fields of development. However, this is going to change. (PRWeb Apr 15, 2004)

Read the full story at http://www.prweb.com/releases/2004/04/prweb118496.htm

]]> http://www.prweb.com/releases/2004/04/prweb118496.htm The Future Battle Between Biopharmaceuticals & Biogenerics http://www.prweb.com/releases/2003/11/prweb90219.htm BioSeeker has analysed the opinions and arguments held by producers of biopharmaceuticals or generic-drug makers as well as regulatory authorities, in order to gain insight on how the near future guidelines will develop. We have reviewed the positions of the FDA and the EMEA, the views on regulatory precedent cases from the biologics industry, the possible route of a comparability study approval, the scope of clinical trial necessary, and the scientific and regulatory issues that must be addressed before future guidelines can be initiated. (PRWeb Nov 21, 2003)

Read the full story at http://www.prweb.com/releases/2003/11/prweb90219.htm

]]> http://www.prweb.com/releases/2003/11/prweb90219.htm